May 9, 2022 -- Illumina and Deerfield Management have entered into a partnership to accelerate drug discovery and development using genetic technologies and artificial intelligence (AI). The five-year partnership will utilize genetic knowledge to strategically invest in the clinical development of therapies with a high probability of success.
Deerfield will employ its capabilities in drug development, combined with Illumina's AI technology to harness genomic data for more guided drug discovery. As a result of this collaboration, the companies aim to reduce the costs associated with drug development and expedite the time to generation of successful therapies.
Through the agreement, Deerfield and Illumina will adopt Illumina's genomics-based discovery platform paired with AI interpretation to select optimal programs. Deerfield will then use its specialized knowledge in translational science to bring these genetically selected therapy targets through the drug development process.
Image courtesy of Illumina.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
